Shares of Endo International PLC (NASDAQ:ENDP) were down 3.7% during trading on Monday . The stock traded as low as $23.05 and last traded at $23.28, with a volume of 4,773,342 shares trading hands. The stock had previously closed at $24.18.

Several analysts recently commented on ENDP shares. Deutsche Bank AG reissued a “buy” rating and set a $31.00 target price on shares of Endo International PLC in a research note on Wednesday, June 15th. Piper Jaffray Cos. downgraded shares of Endo International PLC from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $79.00 to $25.00 in a research report on Friday, May 6th. Stifel Nicolaus reduced their price target on shares of Endo International PLC from $90.00 to $75.00 and set a “buy” rating for the company in a research report on Friday, May 6th. BMO Capital Markets started coverage on shares of Endo International PLC in a research report on Tuesday, June 28th. They issued a “market perform” rating and a $21.00 price target for the company. Finally, Vetr downgraded shares of Endo International PLC from a “strong-buy” rating to a “buy” rating and set a $19.14 price target for the company. in a research report on Thursday, July 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company’s stock. Endo International PLC presently has an average rating of “Hold” and a consensus target price of $39.78.

The company’s market capitalization is $5.17 billion. The firm’s 50 day moving average price is $18.07 and its 200 day moving average price is $27.32.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Monday, August 8th. The company reported $0.86 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.12. The company earned $921 million during the quarter, compared to the consensus estimate of $873.50 million. During the same period in the previous year, the firm posted $1.08 EPS. The business’s quarterly revenue was up 25.3% compared to the same quarter last year. On average, analysts predict that Endo International PLC will post $4.56 earnings per share for the current year.

Several hedge funds have made changes to their positions in ENDP. RS Investment Management Co. LLC raised its stake in shares of Endo International PLC by 29.5% in the fourth quarter. RS Investment Management Co. LLC now owns 543,593 shares of the company’s stock worth $33,279,000 after buying an additional 123,692 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Endo International PLC by 4.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 273,393 shares of the company’s stock worth $16,737,000 after buying an additional 12,234 shares in the last quarter. American International Group Inc. raised its stake in shares of Endo International PLC by 21.8% in the fourth quarter. American International Group Inc. now owns 99,335 shares of the company’s stock worth $6,081,000 after buying an additional 17,770 shares in the last quarter. Finally, Advantus Capital Management Inc raised its stake in shares of Endo International PLC by 2.4% in the fourth quarter. Advantus Capital Management Inc now owns 19,971 shares of the company’s stock worth $1,223,000 after buying an additional 476 shares in the last quarter.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.